Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer

Neal D. Shore, Naveen Kella, Brian Moran, Judd Boczko, Fernando J. Bianco, E. David Crawford, Thaylon Davis, Kirstin M. Roundy, Kristen Rushton, Charles Grier, Rajesh Kaldate, Michael K. Brawer, Mark L Gonzalgo

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

RESULTS: Of the 1,596 patients enrolled in this registry 1,206 were eligible for analysis. There was a significant reduction in the treatment burden recorded at each successive evaluation (p <0.0001), with the mean number of treatments per patient decreasing from 1.72 before the cell cycle progression test to 1.16 in actual followup. The cell cycle progression test caused a change in actual treatment in 47.8% of patients. Of these changes 72.1% were reductions and 26.9% were increases in treatment. For each clinical risk category there was a significant change in treatment modality (intervention vs nonintervention) before vs after cell cycle progression testing (p=0.0002).

CONCLUSIONS: The cell cycle progression test has a significant impact in assisting physicians and patients reach personalized treatment decisions.

PURPOSE: The cell cycle progression test is a validated molecular assay that assesses prostate cancer specific disease progression and mortality risk when combined with clinicopathological parameters. We present the results from PROCEDE-1000, a large, prospective registry designed to evaluate the impact of the cell cycle progression test on shared treatment decision making for patients newly diagnosed with prostate cancer.

MATERIALS AND METHODS: Untreated patients with newly diagnosed prostate adenocarcinoma were enrolled in the study and the cell cycle progression test was performed on the initial prostate biopsy tissue. A set of 4 sequential surveys tracked changes relative to initial therapy recommendations (before cell cycle progression) based on clinicopathological parameters following physician review of the cell cycle progression test result, physician/patient review of the cell cycle progression test results and a minimum of 3 months of clinical followup (actual treatment).

Original languageEnglish (US)
Pages (from-to)612-618
Number of pages7
JournalJournal of Urology
Volume195
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Patient Selection
Prostatic Neoplasms
Cell Cycle
Physicians
Therapeutics
Registries
Prostate
Disease Progression
Decision Making
Adenocarcinoma
Biopsy
Mortality

Keywords

  • biological markers
  • data collection
  • evaluation studies
  • prostatic neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer. / Shore, Neal D.; Kella, Naveen; Moran, Brian; Boczko, Judd; Bianco, Fernando J.; Crawford, E. David; Davis, Thaylon; Roundy, Kirstin M.; Rushton, Kristen; Grier, Charles; Kaldate, Rajesh; Brawer, Michael K.; Gonzalgo, Mark L.

In: Journal of Urology, Vol. 195, No. 3, 01.03.2016, p. 612-618.

Research output: Contribution to journalArticle

Shore, ND, Kella, N, Moran, B, Boczko, J, Bianco, FJ, Crawford, ED, Davis, T, Roundy, KM, Rushton, K, Grier, C, Kaldate, R, Brawer, MK & Gonzalgo, ML 2016, 'Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer', Journal of Urology, vol. 195, no. 3, pp. 612-618. https://doi.org/10.1016/j.juro.2015.09.072
Shore, Neal D. ; Kella, Naveen ; Moran, Brian ; Boczko, Judd ; Bianco, Fernando J. ; Crawford, E. David ; Davis, Thaylon ; Roundy, Kirstin M. ; Rushton, Kristen ; Grier, Charles ; Kaldate, Rajesh ; Brawer, Michael K. ; Gonzalgo, Mark L. / Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer. In: Journal of Urology. 2016 ; Vol. 195, No. 3. pp. 612-618.
@article{98302d97c7d94ea293c0a30dd3d52da7,
title = "Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer",
abstract = "RESULTS: Of the 1,596 patients enrolled in this registry 1,206 were eligible for analysis. There was a significant reduction in the treatment burden recorded at each successive evaluation (p <0.0001), with the mean number of treatments per patient decreasing from 1.72 before the cell cycle progression test to 1.16 in actual followup. The cell cycle progression test caused a change in actual treatment in 47.8{\%} of patients. Of these changes 72.1{\%} were reductions and 26.9{\%} were increases in treatment. For each clinical risk category there was a significant change in treatment modality (intervention vs nonintervention) before vs after cell cycle progression testing (p=0.0002).CONCLUSIONS: The cell cycle progression test has a significant impact in assisting physicians and patients reach personalized treatment decisions.PURPOSE: The cell cycle progression test is a validated molecular assay that assesses prostate cancer specific disease progression and mortality risk when combined with clinicopathological parameters. We present the results from PROCEDE-1000, a large, prospective registry designed to evaluate the impact of the cell cycle progression test on shared treatment decision making for patients newly diagnosed with prostate cancer.MATERIALS AND METHODS: Untreated patients with newly diagnosed prostate adenocarcinoma were enrolled in the study and the cell cycle progression test was performed on the initial prostate biopsy tissue. A set of 4 sequential surveys tracked changes relative to initial therapy recommendations (before cell cycle progression) based on clinicopathological parameters following physician review of the cell cycle progression test result, physician/patient review of the cell cycle progression test results and a minimum of 3 months of clinical followup (actual treatment).",
keywords = "biological markers, data collection, evaluation studies, prostatic neoplasms",
author = "Shore, {Neal D.} and Naveen Kella and Brian Moran and Judd Boczko and Bianco, {Fernando J.} and Crawford, {E. David} and Thaylon Davis and Roundy, {Kirstin M.} and Kristen Rushton and Charles Grier and Rajesh Kaldate and Brawer, {Michael K.} and Gonzalgo, {Mark L}",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.juro.2015.09.072",
language = "English (US)",
volume = "195",
pages = "612--618",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer

AU - Shore, Neal D.

AU - Kella, Naveen

AU - Moran, Brian

AU - Boczko, Judd

AU - Bianco, Fernando J.

AU - Crawford, E. David

AU - Davis, Thaylon

AU - Roundy, Kirstin M.

AU - Rushton, Kristen

AU - Grier, Charles

AU - Kaldate, Rajesh

AU - Brawer, Michael K.

AU - Gonzalgo, Mark L

PY - 2016/3/1

Y1 - 2016/3/1

N2 - RESULTS: Of the 1,596 patients enrolled in this registry 1,206 were eligible for analysis. There was a significant reduction in the treatment burden recorded at each successive evaluation (p <0.0001), with the mean number of treatments per patient decreasing from 1.72 before the cell cycle progression test to 1.16 in actual followup. The cell cycle progression test caused a change in actual treatment in 47.8% of patients. Of these changes 72.1% were reductions and 26.9% were increases in treatment. For each clinical risk category there was a significant change in treatment modality (intervention vs nonintervention) before vs after cell cycle progression testing (p=0.0002).CONCLUSIONS: The cell cycle progression test has a significant impact in assisting physicians and patients reach personalized treatment decisions.PURPOSE: The cell cycle progression test is a validated molecular assay that assesses prostate cancer specific disease progression and mortality risk when combined with clinicopathological parameters. We present the results from PROCEDE-1000, a large, prospective registry designed to evaluate the impact of the cell cycle progression test on shared treatment decision making for patients newly diagnosed with prostate cancer.MATERIALS AND METHODS: Untreated patients with newly diagnosed prostate adenocarcinoma were enrolled in the study and the cell cycle progression test was performed on the initial prostate biopsy tissue. A set of 4 sequential surveys tracked changes relative to initial therapy recommendations (before cell cycle progression) based on clinicopathological parameters following physician review of the cell cycle progression test result, physician/patient review of the cell cycle progression test results and a minimum of 3 months of clinical followup (actual treatment).

AB - RESULTS: Of the 1,596 patients enrolled in this registry 1,206 were eligible for analysis. There was a significant reduction in the treatment burden recorded at each successive evaluation (p <0.0001), with the mean number of treatments per patient decreasing from 1.72 before the cell cycle progression test to 1.16 in actual followup. The cell cycle progression test caused a change in actual treatment in 47.8% of patients. Of these changes 72.1% were reductions and 26.9% were increases in treatment. For each clinical risk category there was a significant change in treatment modality (intervention vs nonintervention) before vs after cell cycle progression testing (p=0.0002).CONCLUSIONS: The cell cycle progression test has a significant impact in assisting physicians and patients reach personalized treatment decisions.PURPOSE: The cell cycle progression test is a validated molecular assay that assesses prostate cancer specific disease progression and mortality risk when combined with clinicopathological parameters. We present the results from PROCEDE-1000, a large, prospective registry designed to evaluate the impact of the cell cycle progression test on shared treatment decision making for patients newly diagnosed with prostate cancer.MATERIALS AND METHODS: Untreated patients with newly diagnosed prostate adenocarcinoma were enrolled in the study and the cell cycle progression test was performed on the initial prostate biopsy tissue. A set of 4 sequential surveys tracked changes relative to initial therapy recommendations (before cell cycle progression) based on clinicopathological parameters following physician review of the cell cycle progression test result, physician/patient review of the cell cycle progression test results and a minimum of 3 months of clinical followup (actual treatment).

KW - biological markers

KW - data collection

KW - evaluation studies

KW - prostatic neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84975896708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975896708&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2015.09.072

DO - 10.1016/j.juro.2015.09.072

M3 - Article

C2 - 26403586

AN - SCOPUS:84975896708

VL - 195

SP - 612

EP - 618

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -